Exelixis reported $2.51B in Assets for its fiscal quarter ending in September of 2026.





Assets Change Date
Acadia Pharmaceuticals USD 1.79B 51.25M Sep/2026
Agios Pharmaceuticals USD 1.06B 44.38M Sep/2026
Akebia Therapeutics USD 342.13M 7.53M Sep/2026
Amgen USD 96.05B 409M Sep/2026
AstraZeneca USD 119.92B 4.09B Sep/2026
Bayer EUR 113.47B 6.18B Sep/2026
BioMarin Pharmaceutical USD 11.57B 154.21M Sep/2026
Bristol-Myers Squibb USD 88.77B 1.14B Sep/2026
Cytokinetics USD 1.82B 99.77M Sep/2026
Eisai JPY 1.52T 33.49B Sep/2026
Eli Lilly USD 148.07B 5.79B Sep/2026
Exelixis USD 2.51B 19.26M Sep/2026
Genmab DKK 12.52B 139M Jun/2026
Glaxosmithkline GBP 71.7B 8.83B Sep/2026
Incyte USD 7.29B 585.39M Sep/2026
Ionis Pharmaceuticals USD 2.91B 81.91M Sep/2026
MacroGenics USD 318.68M 26.72M Sep/2026
Merck USD 132.77B 2.97B Sep/2026
Moderna USD 13.47B 2.51B Sep/2026
Nektar Therapeutics USD 763.27M 482.86M Mar/2026
Neurocrine Biosciences USD 5.63B 268.3M Sep/2026
Novartis USD 117.15B 4.88B Sep/2026
Pfizer USD 204.54B 3.41B Sep/2026
Puma Biotechnology USD 202.86M 7.95M Sep/2025
Sanofi EUR 129.06B 1.04B Jun/2026
Takeda JPY 15.27T 391.77B Sep/2026
Ultragenyx Pharmaceutical USD 1.19B 77M Sep/2026
Xencor USD 770.5M 45.54M Sep/2026